ST3
MCID: SPP010
MIFTS: 50

Suppressor of Tumorigenicity 3 (ST3)

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 57 71
Cervical Carcinoma 57 12 53 16
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 57
Tumor-Suppressor Gene, Hela Cell Type 57
Cervix Carcinoma 71
Tshl 57
Ccts 57
St3 57

Classifications:



External Ids:

OMIM® 57 191181
UMLS 71 C0302592 C1860658

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary: Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to cervical intraepithelial neoplasia and cervical squamous cell carcinoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cellular responses to stimuli. The drugs Aluminum hydroxide and Monophosphoryl lipid A have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and t cells, and related phenotypes are neoplasm and endocrine/exocrine gland

More information from OMIM: 191181

Related Diseases for Suppressor of Tumorigenicity 3

Diseases in the Suppressor of Tumorigenicity 3 family:

Suppressor of Tumorigenicity 11

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 564)
# Related Disease Score Top Affiliating Genes
1 cervical intraepithelial neoplasia 31.6 FHIT CDKN2A
2 cervical squamous cell carcinoma 30.9 TP53 FHIT CDKN2A CDKN1A
3 chronic cervicitis 30.8 TP53 CDKN2A
4 cervical adenocarcinoma 30.8 TP53 CDKN2A CDKN1A
5 cervix uteri carcinoma in situ 30.7 TP53 RB1 FHIT CDKN2A
6 cervix carcinoma 30.6 TP53 MYC CDKN2A BCL2
7 adenocarcinoma 30.3 TP53 RB1 CDKN2A CDKN1A BCL2
8 basaloid squamous cell carcinoma 30.3 TP53 CDKN2A
9 keratinizing squamous cell carcinoma 30.2 TP53 CDKN2A
10 polyploidy 30.2 TP53 CDKN1A
11 endocervical adenocarcinoma 30.1 TP53 MYC CDKN2A
12 human papillomavirus infectious disease 30.0 TP53 MYC FHIT CDKN2A CDKN1A
13 papilloma 30.0 UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
14 squamous cell carcinoma 29.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
15 penile benign neoplasm 29.9 TP53 CDKN2A
16 anogenital venereal wart 29.9 UBE3A TP53 RB1 CDKN2A
17 anal squamous cell carcinoma 29.9 TP53 CDKN2A
18 penile cancer 29.8 UBE3A TP53 CDKN2A
19 retinitis pigmentosa 11 29.8 TP53 MYC CDKN2A
20 lip and oral cavity cancer 29.8 TP53 RB1 CDKN2A
21 vulva squamous cell carcinoma 29.7 TP53 CDKN2A
22 retinoblastoma 29.7 TP53 RB1 MYC CDKN2A CDKN1A BCL2
23 endocervical carcinoma 29.7 TP53 MYC CDKN2A
24 acquired immunodeficiency syndrome 29.6 TP53 MYC BCL2
25 vaginal cancer 29.6 UBE3A TP53 CDKN2A
26 small cell cancer of the lung 29.5 TP53 RB1 MYC CDKN2A BCL2
27 adult t-cell leukemia/lymphoma 29.5 TP53 MYC BCL2
28 endometrial hyperplasia 29.5 TP53 CDKN2A BCL2
29 colon adenocarcinoma 29.5 TP53 MYC CDKN1A BCL2
30 teratoma 29.5 TP53 CDKN2A BCL2
31 skin carcinoma 29.4 TP53 MYC CDKN2A BCL2
32 head and neck cancer 29.4 TP53 MYC CDKN2A BCL2
33 anus cancer 29.4 UBE3A TP53 RB1 CDKN2A
34 b-cell lymphoma 29.4 TP53 RB1 MYC CDKN2A CDKN1A BCL2
35 keratoacanthoma 29.4 TP53 MYC CDKN1A BCL2
36 skin melanoma 29.4 TP53 MYC CDKN2A CDKN1A
37 osteogenic sarcoma 29.4 TP53 RB1 MYC CDKN2A CDKN1A
38 kidney cancer 29.4 TP53 FHIT CDKN2A CA9
39 peripheral nervous system disease 29.3 TP53 MYC CDKN2A BCL2
40 leiomyosarcoma 29.3 TP53 RB1 CDKN2A BCL2
41 adenoma 29.2 TP53 MYC CDKN2A BCL2
42 testicular cancer 29.2 TP53 MYC BCL2
43 pancreatic adenocarcinoma 29.1 TP53 CDKN2A CDKN1A BCL2
44 melanoma, cutaneous malignant 1 29.1 TP53 RB1 MYC CDKN2A CDKN1A
45 oropharynx cancer 29.1 UBE3A TP53 CDKN2A BCL2
46 basal cell carcinoma 29.1 TP53 CDKN2A CDKN1A BCL2
47 fanconi anemia, complementation group a 29.1 TP53 RB1 MYC CDKN2A CDKN1A
48 nasopharyngeal carcinoma 29.0 TP53 MYC CDKN2A CA9 BCL2
49 myelodysplastic syndrome 29.0 TP53 MYC FHIT CDKN2A BCL2
50 glioblastoma 29.0 TP53 RB1 MYC CDKN2A CDKN1A BCL2

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM®:

191181 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.06 BCL2 CDKN1A CDKN2A FHIT MYC RB1
2 endocrine/exocrine gland MP:0005379 9.92 BCL2 CA9 CDKN1A CDKN2A MYC RB1
3 no phenotypic analysis MP:0003012 9.91 CDKN1A CDKN2A MYC RB1 TP53 UBE3A
4 pigmentation MP:0001186 9.88 BCL2 CDKN2A MYC RB1 TP53
5 adipose tissue MP:0005375 9.88 BCL2 CDKN1A MYC PLIN3 RB1 TP53
6 digestive/alimentary MP:0005381 9.86 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
7 immune system MP:0005387 9.81 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
8 hearing/vestibular/ear MP:0005377 9.77 BCL2 CDKN1A MYC RB1 TP53
9 hematopoietic system MP:0005397 9.65 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
10 integument MP:0010771 9.28 BCL2 CDKN1A CDKN2A FHIT MYC RB1

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2 Monophosphoryl lipid A Phase 4
3 Vaccines Phase 4
4 Immunologic Factors Phase 4
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
6
Metronidazole Approved Phase 2, Phase 3 443-48-1, 69198-10-3 4173
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60699 60700
9
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
10
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
11
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556 135565230
12
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
13
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
14
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
15
Tirapazamine Investigational Phase 3 27314-97-2 135413511
16 Endostatins Phase 3
17 Endostar protein Phase 3
18 topoisomerase I inhibitors Phase 3
19 Endothelial Growth Factors Phase 3
20 Mitogens Phase 3
21 Anti-Infective Agents Phase 2, Phase 3
22 Antiprotozoal Agents Phase 2, Phase 3
23 Antiparasitic Agents Phase 2, Phase 3
24 Anti-Bacterial Agents Phase 3
25 Antibiotics, Antitubercular Phase 3
26 Liposomal doxorubicin Phase 3
27 Folic Acid Antagonists Phase 3
28 Vinca Alkaloids Phase 3
29
Etoposide Approved Phase 2 33419-42-0 36462
30
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2
31
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
32
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
33
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
34
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
35
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
36
Cetuximab Approved Phase 2 205923-56-4
37
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
38
Bupropion Approved Phase 2 31677-93-7, 34841-39-9, 34911-55-2 444
39
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
40
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
43
Lenograstim Approved, Investigational Phase 2 135968-09-1
44
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
45
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
46
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
47
Afatinib Approved Phase 2 439081-18-2, 850140-72-6 53445376 10184653
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Trametinib Approved Phase 2 871700-17-3 11707110
50
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Completed NCT03105856 Phase 4
2 Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes) Enrolling by invitation NCT05237947 Phase 4
3 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)") Enrolling by invitation NCT03180034 Phase 4
4 Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma Unknown status NCT00806117 Phase 3
5 A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma Unknown status NCT03086681 Phase 3 Endostar;DDP
6 Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma Unknown status NCT01000415 Phase 3
7 Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma Unknown status NCT01554397 Phase 2, Phase 3 Cisplatin
8 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
9 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Unknown status NCT02595554 Phase 3 Paclitaxel;Cisplatin
10 Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma" Completed NCT02083211 Phase 3 mAb Nimotuzumab
11 Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line. Completed NCT03413579 Phase 3
12 To Study the Factors Affecting Treatment Responses in Patients With Uterine Cervical Carcinoma Undergoing Neoadjuvant Chemotherapy Completed NCT05384366 Phase 3 Neoadjuvant chemotherapy
13 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
14 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
15 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
16 Collaborative Corneal Transplantation Studies (CCTS) Completed NCT00000137 Phase 3
17 A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma Recruiting NCT02584478 Phase 3 AL3818;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin
18 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer Recruiting NCT05235516 Phase 3 AK104;cisplatin;Placebo
19 An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma Active, not recruiting NCT03257267 Phase 3 Cemiplimab;Investigator Choice (IC) Chemotherapy
20 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Active, not recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
21 Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer") Active, not recruiting NCT03728881 Phase 3
22 PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer. Not yet recruiting NCT05581121 Phase 3
23 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
24 Anti-PD-1 Antibody Camrelizumab Combined With Cisplatin/Paclitaxel/Bevacizumab for Recurrent or Advanced Cervical Neuroendocrine Carcinomas: A Single Arm, Phase II Trial Unknown status NCT04635956 Phase 2 Drug therapy
25 Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma. Unknown status NCT00039884 Phase 2 NESP - Novel Erythropoiesis Stimulating Protein
26 An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma Unknown status NCT00292955 Phase 2 Cetuximab
27 An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix Unknown status NCT02492503 Phase 1, Phase 2 Paclitaxel and carboplatin
28 Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma. Completed NCT03540407 Phase 2
29 Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial Completed NCT04188847 Phase 2 Chemotherapy plus apatinib
30 Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Single Center, Open, Phase II Trial Completed NCT04188860 Phase 2 A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
31 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
32 A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies Completed NCT01693783 Phase 2
33 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
34 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
35 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
36 Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma Completed NCT00003445 Phase 2 docetaxel
37 HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma: Clinical Trial Completed NCT02523365 Phase 1, Phase 2
38 Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study Completed NCT00184093 Phase 1, Phase 2 Gemcitabine
39 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
40 A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
41 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
42 A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma Completed NCT00257816 Phase 2 Topotecan;Cisplatin
43 A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies Completed NCT02025985 Phase 2 Selinexor
44 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
45 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
46 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Completed NCT03180294 Phase 2 Bupropion 150 mg XL;Placebo
47 A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) Completed NCT00081263 Phase 2 Celecoxib
48 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
49 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
50 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

Organs/tissues related to Suppressor of Tumorigenicity 3:

MalaCards : Cervix, Lymph Node, T Cells, Breast, Bone Marrow, Prostate, Lung

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 12419)
# Title Authors PMID Year
1
Interstitial deletion of 11q13 sequences in HeLa cells. 62 57
10959095 2000
2
Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. 62 57
7887426 1995
3
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 62 57
8041728 1994
4
Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. 62 57
1680288 1991
5
Genetic characteristics of the HeLa cell. 62 57
1246620 1976
6
Short tandem repeat profiling provides an international reference standard for human cell lines. 57
11416159 2001
7
Cell culture forensics. 57
11438719 2001
8
East Hela and West Hela, in memory of Stella Mamaeva, 1939-1995. 57
8964054 1996
9
Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. 57
2577469 1989
10
Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. 57
2881780 1986
11
Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. 57
2877730 1986
12
Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. 57
3956263 1986
13
Suppression of tumorigenicity. 57
7140370 1982
14
Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. 57
7323948 1981
15
Cross-contamination of cells in culture. 57
6451928 1981
16
Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes. 57
6934067 1980
17
Characteristics of HeLa strains: permanent vs. variable features. 57
7002488 1980
18
Suppression of malignancy in human cells. 57
1264187 1976
19
HeLa cultures defined. 57
1246601 1976
20
Banded marker chromosomes as indicators of intraspecies cellular contamination. 57
4469665 1974
21
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. 57
4942173 1971
22
Apparent Hela cell contamination of human heteroploid cell lines. 57
5641128 1968
23
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. 53 62
20351093 2010
24
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. 53 62
20067769 2010
25
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 53 62
20429915 2010
26
Constitutive HIF-1 activity in malignant melanoma. 53 62
20185296 2010
27
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 53 62
20395210 2010
28
HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. 53 62
20026098 2010
29
Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. 53 62
19953094 2010
30
Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. 53 62
19362787 2009
31
Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. 53 62
19935879 2009
32
[Involvement of human papillomavirus in upper aero-digestive tracts cancers]. 53 62
19744917 2009
33
HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 53 62
19775342 2009
34
Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. 53 62
19427027 2009
35
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. 53 62
19589137 2009
36
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. 53 62
19216720 2009
37
The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. 53 62
19563645 2009
38
Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. 53 62
19441892 2009
39
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. 53 62
19202550 2009
40
Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. 53 62
19476635 2009
41
[Inhibitive effect of E1A gene on the cell growth of human cervical carcinoma cell in vitro]. 53 62
19483289 2009
42
The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. 53 62
18716870 2009
43
Immunohistochemical studies of trophoblastic tumors. 53 62
19145204 2009
44
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. 53 62
19327639 2009
45
No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. 53 62
19263211 2009
46
Differential tissue-specific protein markers of vaginal carcinoma. 53 62
19367286 2009
47
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 53 62
19251084 2009
48
Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. 53 62
19100258 2009
49
Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. 53 62
19331227 2009
50
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. 53 62
19148475 2009

Variations for Suppressor of Tumorigenicity 3

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 UBE3A TP53 RB1 MYC CDKN2A CDKN1A
2
Show member pathways
13.39 TP53 RB1 MYC CDKN2A CDKN1A CA9
3
Show member pathways
13.38 TP53 RB1 MYC CDKN2A CDKN1A BCL2
4
Show member pathways
12.85 TP53 MYC CDKN2A CDKN1A BCL2
5
Show member pathways
12.65 CDKN1A CDKN2A RB1 TP53
6 12.63 BCL2 CDKN1A CDKN2A MYC TP53
7
Show member pathways
12.53 TP53 MYC CDKN1A BCL2
8
Show member pathways
12.53 TP53 RB1 MYC CDKN1A BCL2
9
Show member pathways
12.49 BCL2 CDKN1A CDKN2A FHIT MYC RB1
10 12.46 TP53 RB1 CDKN2A CDKN1A
11
Show member pathways
12.43 RB1 MYC CDKN2A CDKN1A
12
Show member pathways
12.4 TP53 RB1 MYC CDKN1A
13
Show member pathways
12.31 RB1 MYC CDKN2A CDKN1A
14 12.21 MYC CDKN2A CDKN1A CA9
15
Show member pathways
12.16 TP53 RB1 CDKN1A BCL2
16
Show member pathways
12.14 TP53 RB1 MYC CDKN1A BCL2
17
Show member pathways
12.14 TP53 RB1 MYC CDKN2A CDKN1A
18 12.11 TP53 MYC CDKN1A
19 12.09 TP53 RB1 MYC BCL2
20
Show member pathways
12.07 TP53 CDKN2A CDKN1A
21
Show member pathways
12.04 TP53 RB1 MYC CDKN1A
22
Show member pathways
12.04 TP53 RB1 CDKN2A CDKN1A
23 11.94 TP53 RB1 MYC
24 11.94 TP53 TAP1 RB1 CDKN1A BCL2
25 11.93 MYC CDKN2A CDKN1A
26 11.91 BCL2 CDKN1A MYC TP53
27 11.88 TP53 MYC CDKN1A BCL2
28 11.82 TP53 RB1 CDKN2A CDKN1A BCL2
29 11.78 TP53 RB1 MYC CDKN1A
30 11.74 MYC CDKN2A CDKN1A BCL2
31 11.73 RB1 MYC CDKN1A
32 11.69 TP53 RB1 CDKN2A CDKN1A
33 11.68 TP53 MYC CDKN2A
34 11.67 TP53 MYC CDKN1A
35 11.63 RB1 MYC CDKN2A CDKN1A
36 11.62 MYC CDKN1A BCL2
37 11.57 RB1 CDKN2A CDKN1A
38 11.57 CDKN2A RB1 TP53 UBE3A
39 11.56 TP53 MYC CDKN1A
40 11.47 UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
41 11.45 TP53 MYC CDKN1A
42 11.42 TP53 RB1 MYC FHIT CDKN1A BCL2
43 11.35 RB1 MYC CDKN2A
44 11.34 TP53 RB1 MYC BCL2
45 11.29 TP53 RB1 CDKN2A
46 11.16 TP53 RB1 MYC CDKN2A CDKN1A
47 11.12 TP53 BCL2
48 11.12 MYC CDKN2A
49 11.06 TP53 BCL2

GO Terms for Suppressor of Tumorigenicity 3

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 response to xenobiotic stimulus GO:0009410 10.14 TP53 MYC CA9 BCL2
2 negative regulation of cell population proliferation GO:0008285 10.14 TP53 RB1 CDKN2A CDKN1A BCL2
3 regulation of cell cycle GO:0051726 10.06 TP53 RB1 CDKN2A CDKN1A BCL2
4 neuron apoptotic process GO:0051402 10.05 TP53 RB1 BCL2
5 cellular response to xenobiotic stimulus GO:0071466 10.03 TP53 RB1 MYC
6 cellular senescence GO:0090398 10 TP53 CDKN2A CDKN1A
7 cellular response to glucose starvation GO:0042149 9.99 TP53 PLIN3 BCL2
8 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.95 BCL2 CDKN1A RB1
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.9 TP53 CDKN1A
10 negative regulation of glial cell proliferation GO:0060253 9.87 TP53 RB1
11 Ras protein signal transduction GO:0007265 9.86 CDKN1A CDKN2A RB1 TP53
12 regulation of mitotic cell cycle GO:0007346 9.85 CDKN1A RB1 TP53
13 response to gamma radiation GO:0010332 9.85 TP53 MYC BCL2
14 regulation of G2/M transition of mitotic cell cycle GO:0010389 9.76 CDKN2A CDKN1A
15 B cell lineage commitment GO:0002326 9.76 TP53 BCL2
16 T cell lineage commitment GO:0002360 9.67 TP53 BCL2
17 replicative senescence GO:0090399 9.63 TP53 CDKN2A CDKN1A
18 signal transduction by p53 class mediator GO:0072331 9.61 TP53 CDKN1A
19 negative regulation of mitotic cell cycle GO:0045930 9.5 TP53 RB1 BCL2
20 G1/S transition of mitotic cell cycle GO:0000082 9.5 RB1 MYC CDKN1A BCL2
21 negative regulation of cell growth GO:0030308 9.32 TP53 RB1 CDKN2A CDKN1A BCL2

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.85 TP53 RB1 FHIT CDKN1A BCL2
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.56 CDKN2A CDKN1A
3 disordered domain specific binding GO:0097718 9.35 TP53 RB1 CDKN2A
4 molecular function activator activity GO:0140677 9.1 TP53 CDKN1A CA9

Sources for Suppressor of Tumorigenicity 3

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....